Biotech Values

[DewDiligence]

Addendum on the sub-Q formulation:

I’ve reviewed GENR’s PR from 4/22/04 (#msg-2914787) as well as my notes from GENR’s CC on the same date.

There was no indication in either the PR or the CC that GENR intended to pursue a subcutaneous formulation of Squalamine for AMD. This leads me to wonder if the subcutaneous formulation might have been an afterthought designed to compensate for some perceived deficiency in the AMD program. Feedback welcomed.